Medibank Private (ASX: MPL) has released its FY26 results, and at first glance there is plenty for shareholders to celebrate.
Net profit jumped 27.5%. The dividend increased 6.7%. Medibank Health grew profit by more than 30%.
Those are strong numbers. But as an income investor, I do not want to stop at the headline profit number. I care about a different set of questions: is the underlying business getting stronger, is the dividend sustainable, and am I being paid enough for the risks I am taking?
After going through Medibank’s FY26 accounts and investor materials, my view is that this was a good result from a very good business, but not quite as spectacular as the 27.5% statutory profit increase makes it sound.
Portfolio Impact Summary
| Income lens | FY26 read-through | MyIncomeFactory view |
|---|---|---|
| Cash dividend | Full-year dividend rose 6.7% to 19.2 cents per share, fully franked. | Good income growth, especially with franking credits for eligible Australian investors. |
| Dividend cover | Payout ratio was 83% of underlying NPAT, within the 75%-85% target range. | Covered, but close to the top of the preferred range. |
| Underlying earnings | Underlying NPAT rose 2.9% to $636.8 million. | Solid, not spectacular. Future dividend growth needs more earnings growth. |
| Growth option | Medibank Health segment profit rose 31.3% to $100.7 million. | This is the most interesting long-term growth lever. |
| Main risk | Cyber-related litigation and regulatory matters remain unresolved. | A genuine tail risk that income investors should not ignore. |
First, the numbers that matter
Medibank reported FY26 revenue of $9.12 billion, up 5.9%, while group operating profit increased 6.7% to $813.5 million. Statutory net profit attributable to shareholders rose 27.5% to $638.7 million.
But statutory profit is not the number I am focusing on. Medibank’s underlying NPAT increased just 2.9% to $636.8 million, while underlying earnings per share rose to 23.1 cents.
The large difference is mostly because FY25 contained a $128 million normalisation relating to the finalisation of Medibank’s COVID-19 reserve. So the cleaner income-investor summary is this: underlying earnings grew about 3%, while the dividend grew nearly 7%.
That is still a decent outcome. But it is very different from saying earnings grew 27.5%.
The Good
1. Another fully franked dividend increase
This is the part that matters most to my Income Factory. Medibank lifted its full-year dividend from 18.0 cents to 19.2 cents per share, an increase of 6.7%.
The final dividend is 10.9 cents per share and, importantly for Australian income investors, the dividend remains fully franked. At a share price around $4.60, based on delayed market data at about 14:45 AEST on 20 August 2026, the 19.2-cent annual dividend represents a cash yield of about 4.2%. For an Australian investor able to use franking credits, the grossed-up yield is roughly 6.0%.
That moves Medibank closer to the sort of income return I look for. It is not an exceptionally high-yielding stock, but I am happy to accept a slightly lower starting yield when I believe the underlying dividend is defensive and has room to grow.
The catch is the payout ratio. Medibank paid out 83% of underlying earnings, up from 80.1% last year. Management’s target range is 75% to 85%, so the dividend is approaching the top of the company’s preferred range.
That is not immediately worrying, but future dividend growth increasingly needs to come from earnings growth rather than simply distributing a larger share of earnings.
2. The core insurance machine keeps working
Health insurance is not an exciting business. That is partly why I like it.
Health Insurance operating profit increased 3.8% to $769.8 million. The presentation also showed resident policyholder growth of 22,100, or 1.1%, with the Medibank brand growing 0.6% and ahm growing 2.4%.
Those numbers do not scream growth. They scream stability. Stability is valuable in an income portfolio, especially beside more cyclical dividend stocks.
3. Medibank Health could become the real growth engine
The most interesting number in the result may not come from health insurance at all. Medibank Health increased revenue 30.8% to $634.8 million, while segment profit jumped 31.3% to $100.7 million.
This includes primary care, home-based healthcare, wellbeing services and other healthcare delivery activities. Medibank expects this division’s profit to grow by around 25% in FY27, helped by a full-year contribution from Better Medical.
For dividend investors, the attraction is a defensive cash-generating core business funding a faster-growing healthcare services division. That does not guarantee success, but it gives Medibank a more interesting growth path than a mature insurer would otherwise have.
The Bad
1. Customer growth is not particularly strong
Resident policyholders increased 1.1% during FY26, but Medibank’s resident private health insurance market share slipped from 26.5% to 26.3%.
The competitive environment also intensified late in FY26, with competitors pursuing more aggressive growth and aggregators increasing marketing activity. I prefer Medibank protecting margins rather than chasing customers through discounts, but shrinking market share cannot be ignored indefinitely.
2. Non-resident insurance is weaker
Medibank’s non-resident policy units declined 2.3%. Management pointed to weaker student numbers after tighter migration settings and the natural run-off of larger post-border-reopening student cohorts.
There was some offset from worker growth, and management expects non-resident gross profit to recover in FY27. For now, though, this part of the business is clearly weaker than the resident business.
3. Lower rates are now an earnings headwind
One slightly unusual aspect of owning an insurer is that lower interest rates are not always good news. Medibank holds a substantial investment portfolio to support its regulatory reserves.
FY26 net investment income fell 13.9% from $207.8 million to $178.9 million, with management pointing to the lower average RBA cash rate. This is not a problem with the operating business, but it does mean part of the previous earnings tailwind from higher rates is disappearing.
The Ugly
The $74.8 million benefit that does not repeat
FY26 resident health insurance claims benefited from a $74.8 million non-recurring claims benefit. That benefit unwinds in FY27.
Yet Medibank still expects its FY27 resident health insurance gross margin to remain broadly consistent with FY26, subject to the April 2027 premium increase. If management can hold margins despite losing that tailwind, I would regard that as a strong result. If margins start falling, FY26 may turn out to have been closer to peak profitability than it first appeared.
Cyber risk still is not finished
Four years after Medibank’s 2022 cyberattack, the financial consequences still have not been completely resolved. Medibank incurred another $34.9 million of cybercrime-related costs in FY26 covering its security uplift, legal costs and regulatory matters.
Management expects these costs to fall below $20 million in FY27, excluding any financial impact from regulatory findings or litigation. Medibank is still dealing with civil penalty proceedings, consumer and shareholder class actions, and a $250 million APRA supervisory capital adjustment.
I do not think this makes Medibank uninvestable. But I also would not pretend the issue has disappeared. For an income investor, this remains a low-probability but potentially high-impact risk in the background.
Would I buy Medibank after the result?
This is where the share-price reaction matters. The draft valuation reference before the result was around $5.03, which implied a cash yield of roughly 3.8% and a price near 22 times FY26 underlying EPS.
Delayed market data I checked on 20 August 2026 showed MPL closer to $4.60 after a sharp fall on the day. At that level, the historical FY26 dividend yield is just over 4% before franking, and the grossed-up yield is closer to 6% for eligible investors.
That makes the income equation more interesting. It does not make the stock automatically cheap. Underlying profit growth was only 2.9%, policyholder growth remains modest, a $74.8 million claims benefit will not repeat, and cyber litigation remains unresolved.
For me, Medibank has moved from “quality but probably too expensive” toward “quality worth watching more closely”.
My Income Factory verdict
Medibank remains the sort of company I would be comfortable owning for income. The core insurance franchise is strong, the dividend continues to grow and is fully franked, the balance sheet looks healthy, and Medibank Health is starting to become large enough to influence the investment case.
But FY26 was not quite the 27.5% earnings-growth story suggested by the headline result. Underlying profit increased only 2.9%, customer growth is modest, lower investment income is a headwind, the one-off claims benefit unwinds next year, and cyber-related risks remain unresolved.
My approach would be: hold if I already own it, watch patiently if I do not, and become more interested if the valuation gives me a better starting income yield without ignoring the risks.
That is exactly how I want my Income Factory to operate. I do not need every investment to be exciting. I need businesses capable of producing dependable cash flow, growing that cash flow over time, and letting me sleep comfortably while I wait.
What I am watching next
- Can FY27 margins remain stable after the $74.8 million claims benefit disappears?
- Can Medibank Health deliver another roughly 25% increase in segment profit?
- Can resident policyholder and market-share growth improve without sacrificing margins?
- How much financial impact, if any, emerges from unresolved cyber litigation and regulatory proceedings?
Those answers will tell me much more about Medibank’s future dividend potential than the 27.5% statutory profit increase announced this year.
Sources
- Medibank Private FY26 Appendix 4E, Directors’ Report and Financial Report, 20 August 2026
- Medibank FY26 full-year results presentation, 20 August 2026
- Medibank Investor Centre: results and reports
- Intelligent Investor delayed MPL market data, checked 20 August 2026
Disclosure: This article is a personal investment journal and is provided for general information only. It is not financial advice and does not take into account your objectives, financial situation or needs. Always do your own research before making an investment decision.
AI disclosure: This article was drafted with AI assistance and reviewed for clarity, source accuracy and relevance to Australian income investors before publication.